Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             191 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 A cathepsin k inhibitor (alone or in combination with zoledronic acid) inhibits the progression of breast cancer bone metastases Le Gall, C.
 2006
 38 3S1 p. 55-56
2 p.
 artikel
2 A computational model explains bisphosphonate binding affinity differences on hydroxyapatite Ebetino, F.H.
 2006
 38 3S1 p. 48-49
2 p.
 artikel
3 ADAMs in the formation of foreign body giant cells and osteoclasts Guofeng, M.A.
 2006
 38 3S1 p. 28-29
2 p.
 artikel
4 Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast Oshima, K.
 2006
 38 3S1 p. 29-
1 p.
 artikel
5 Age-specific characteristics of axial skeleton mineralization in children Scheplyagina, L.A.
 2006
 38 3S1 p. 17-
1 p.
 artikel
6 72a Inorganic phosphate stimulates matrix GLA protein expression in growth plate chondrocytes through the ERK signaling pathway Julien, M.
 2006
 38 3S1 p. 35-36
2 p.
 artikel
7 Alkylamines prevent osteoclast formation and activity by inhibiting the mevalonate pathway Thompson, K.
 2006
 38 3S1 p. 31-
1 p.
 artikel
8 Alterations in canine vertebral bone turnover, mineralization, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate Allen, M.R.
 2006
 38 3S1 p. 42-
1 p.
 artikel
9 A novel bisphosphonate, TRK-530, for periodontitis Takeyama, S.
 2006
 38 3S1 p. 31-
1 p.
 artikel
10 A novel LRP5 mutation in a patient with increased bone mass results in reduced DKK1-inhibition Balemans, W.
 2006
 38 3S1 p. 6-7
2 p.
 artikel
11 Anti-nociceptive effects of the bisphosphonate risedronate in a syngeneic mouse model of bone cancer pain Hald, A.
 2006
 38 3S1 p. 51-
1 p.
 artikel
12 A phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases despite standard bisphosphonate (BP) therapy Clemons, M.
 2006
 38 3S1 p. 71-
1 p.
 artikel
13 A randomized trial investigating different durations of adjuvant androgen deprivation with and without zoledronic acid in the treatment of localized carcinoma of the prostate Denham, J.
 2006
 38 3S1 p. 72-
1 p.
 artikel
14 Arrestin-regulated genes in osteoblasts exposed to intermittent or continuous PTH Bianchi, E.N.
 2006
 38 3S1 p. 8-
1 p.
 artikel
15 Association of c-SRC and adhesion and degranulation-promoting adaptor protein (ADAP) in osteoclastogenesis in vitro Koga, S.
 2006
 38 3S1 p. 27-
1 p.
 artikel
16 BIM is a novel regulator of glucocorticoid-induced apoptosis in osteoblasts Espina, B.
 2006
 38 3S1 p. 10-
1 p.
 artikel
17 Bishosphonates inhibit bone resorption in multicentric reticulohistiocytosis Adamopoulos, I.E.
 2006
 38 3S1 p. 65-
1 p.
 artikel
18 Bisphosphonate rescue in distraction osteogenesis: A case series Little, D.G.
 2006
 38 3S1 p. 80-
1 p.
 artikel
19 Bisphosphonates potency in vivo and the compliance of the molecules with hydroxyapatite crystal unit structure Sarig, S.
 2006
 38 3S1 p. 62-
1 p.
 artikel
20 Bisphosphonates treatment for cancer induced osteopenia: effect on bone mineral density (BMD) Rodríguez, E.
 2006
 38 3S1 p. 82-83
2 p.
 artikel
21 Bisphosphonate use for metastatic breast cancer –too much? too little? too late to start again? Vanhuyse, M.
 2006
 38 3S1 p. 85-
1 p.
 artikel
22 BMP-2 treatment produces an attenuated response in a mouse model of type 1 neurofibromatosis Schindeler, A.
 2006
 38 3S1 p. 18-
1 p.
 artikel
23 21 Bone remodeling and the roles of nuclear receptor Kato, S.
 2006
 38 3S1 p. 13-
1 p.
 artikel
24 Bone resorption marker directed therapy for metastatic bone disease Lester, J.
 2006
 38 3S1 p. 79-
1 p.
 artikel
25 Bone strength parameters under effect of glucocorticoids and zoledronic acid in rats Luzin, V.
 2006
 38 3S1 p. 56-
1 p.
 artikel
26 BP-associated avascular necrosis (AN) of the jaws: Histological findings Hoefert, S.
 2006
 38 3S1 p. 76-
1 p.
 artikel
27 76 Carbon dioxide rich water bathing increases local vegf secretion and CD34+CD33+ endothelial progenitor cells in ischemic lower limbs of DM and ASO patients Saito, K.
 2006
 38 3S1 p. 37-
1 p.
 artikel
28 Cardiotrophin-1 regulates osteoclast and osteoblast function in a manner distinct from other gp130 cytokines Sims, N.A.
 2006
 38 3S1 p. 30-
1 p.
 artikel
29 77 Catch-up growth in experimental chronic renal failure (CRF). Effect of growth hormone (GH) Molinos, I.
 2006
 38 3S1 p. 37-
1 p.
 artikel
30 Cellular immunity in dialysis patients treated with ibandronate for 48 weeks Bergner, R.
 2006
 38 3S1 p. 67-68
2 p.
 artikel
31 Central control of cortical bone homeostasis: Neuropeptide Y exerts a negative effect on cortical bone formation Baldock, P.A.
 2006
 38 3S1 p. 6-
1 p.
 artikel
32 Changes of bone quality of cortical bone formed under alendronate treatment were detected by microbeam X-ray diffraction analysis Kashii, M.
 2006
 38 3S1 p. 12-13
2 p.
 artikel
33 Characteristics and toxicity profile of patients receiving more than 2 years treatment with bisphosphonates for bone metastases from breast cancer Lester, J.E.
 2006
 38 3S1 p. 79-80
2 p.
 artikel
34 Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: Role in the interactions with Receptor Activator of Nuclear Factor kB Ligand (RANKL) and RANK Théoleyre, S.
 2006
 38 3S1 p. 25-26
2 p.
 artikel
35 Colony-stimulating factor-1 does not induce irreversible commitment of marrow precursors to the macrophage lineage Wetterwald, Antoinette
 2006
 38 3S1 p. 32-
1 p.
 artikel
36 Combination of irradiation and bisphosphonates in the therapy of bone metastases Krempien, R.
 2006
 38 3S1 p. 76-
1 p.
 artikel
37 Combined administration of darbepoetin and zoledronic acid in the treatment of refractory multiple myeloma (MM) Improta, S.
 2006
 38 3S1 p. 75-
1 p.
 artikel
38 Comparison of renal impairment in multiple myeloma patients treated with zoledronic acid or ibandronate: A retrospective review Antràs, L.
 2006
 38 3S1 p. 87-
1 p.
 artikel
39 Concordance rate of osteoporosis self-assessment tool for Asians and dual energy X-ray absorptiometry in diagnosis of osteoporosis Lu, Chunyan
 2006
 38 3S1 p. 14-
1 p.
 artikel
40 Continuous or repeated intermittent low-dose therapy with zoledronic acid induces a sustained inhibition of tumor cell trafficking to bone in vivo Guglielmi, J.
 2006
 38 3S1 p. 44-45
2 p.
 artikel
41 Crossover reaction of ibandronate elisa with zoledronate Nauth, B.
 2006
 38 3S1 p. 58-
1 p.
 artikel
42 Crystal structure of a dead-end complex with two isopentenyl diphosphate molecules sheds light on substrate recognition by human FPPS Rondeau, J.-M.
 2006
 38 3S1 p. 60-61
2 p.
 artikel
43 Crystal structures and molecular interactions of risedronate and zoledronate with human farnesyl diphosphate synthase Kavanagh, K.L.
 2006
 38 3S1 p. 53-
1 p.
 artikel
44 Cytosolic entry of Bisphosphonates into macrophages and osteoclasts requires fluid-phase endocytosis and endosomal acidification Thompson, Keith
 2006
 38 3S1 p. 47-
1 p.
 artikel
45 Decreased bone formation with ageing: Consequence of an imbalance between BMP agonists and antagonists? Egrise, D.
 2006
 38 3S1 p. 7-8
2 p.
 artikel
46 Decreasing the catabolic response by a single bisphosphonate infusion shortens the healing time in hemicallotasis operations Tägil, M.
 2006
 38 3S1 p. 84-85
2 p.
 artikel
47 Deletion of hypothalamic neuropeptide Y2-receptors in adult mice protects against continued ovariectomy-induced bone loss Allison, S.J.
 2006
 38 3S1 p. 6-
1 p.
 artikel
48 Descriptive analysis of bisphosphonates use in patients with cancer and bone metastasis Launay-Vacher, V.
 2006
 38 3S1 p. 78-
1 p.
 artikel
49 Do adenosine and glutamate-mediated signalling pathways interact in osteoblasts and osteocytes? Mason, D.J.
 2006
 38 3S1 p. 15-16
2 p.
 artikel
50 Dose escalation of ibandronate in patients with multiple myeloma and end-stage renal disease – an open label study Henrich, D.
 2006
 38 3S1 p. 74-
1 p.
 artikel
51 Dynamic measurement system of interfragmentary movements in patients treated with ilizarov external fixation Kuiper, J.-H.
 2006
 38 3S1 p. 10-
1 p.
 artikel
52 Editorial Board 2006
 38 3S1 p. ii-iii
nvt p.
 artikel
53 Effect of nicotine on bone healing in mandibular distraction osteogenesis Zheng, L.W.
 2006
 38 3S1 p. 21-22
2 p.
 artikel
54 Effect of olpadronate on post-tooth extraction healing in rats. A cronodinamic study Sivak, M.G.
 2006
 38 3S1 p. 30-
1 p.
 artikel
55 Effect of serum containing chinese herb of strengthening kidney on proliferation and differentiation of human osteoblast Luo, Z.G.
 2006
 38 3S1 p. 14-
1 p.
 artikel
56 Effect of two-year discontinuation after five years of alendronate treatment in patients with postmenopausal osteoporosis Cokolic, Miro
 2006
 38 3S1 p. 71-72
2 p.
 artikel
57 Effects of chronic chlorobenzene administration on the femur in rats Valkusz, Zs.
 2006
 38 3S1 p. 63-
1 p.
 artikel
58 Effects of ibandronate and zoledronic acid in a model of inflammatory pain Bianchi, M.
 2006
 38 3S1 p. 43-44
2 p.
 artikel
59 Effects of increasing fruit and vegetable intake on bone turnover in postmenopausal osteopenic women Ebrahimof, S.
 2006
 38 3S1 p. 25-
1 p.
 artikel
60 Effects of mevastatin on grafted bone in MRL/MpJ mice Sugazaki, M.
 2006
 38 3S1 p. 12-
1 p.
 artikel
61 Effects of Zoledronic acid and Paclitaxel on endothelial cells in vitro Michailidou, M.
 2006
 38 3S1 p. 57-58
2 p.
 artikel
62 Effects of zoledronic acid on apoptosis in tumour cell lines; repeated low dosing compared to continuous treatment Holen, I.
 2006
 38 3S1 p. 51-52
2 p.
 artikel
63 Efficacy of zoledronic acid for the prevention of bone metastases in patients with non-small cell lung cancer Scagliotti, G.
 2006
 38 3S1 p. 83-
1 p.
 artikel
64 Efficacy of zoledronic acid for the reduction of bone marrow tumor cells in breast cancer patients receiving adjuvant therapy Solomayer, E.-F.
 2006
 38 3S1 p. 84-
1 p.
 artikel
65 Elevated expression of FGF23 in bone in an in vivo murine model of primary hyperparathyroidism Imanishi, Y.
 2006
 38 3S1 p. 12-
1 p.
 artikel
66 Elevated serum activity of TRACP5B in osteosarcoma patients (OS) is associated with an aggressive phenotype and with OS induced osteoclast activity Avnet, S.
 2006
 38 3S1 p. 23-
1 p.
 artikel
67 Endochondral repair and development proceed normally during zoledronic acid treatment McDonald, M.M.
 2006
 38 3S1 p. 56-57
2 p.
 artikel
68 Enhancement of BMP signaling by cyclic AMP: Its role and mechanism Ohta, Y.
 2006
 38 3S1 p. 17-
1 p.
 artikel
69 Estrogen receptor alpha expression in osteocytes has a regional distribution regulated preferentially by estrogen but not by mechanical strain Zaman, G.
 2006
 38 3S1 p. 21-
1 p.
 artikel
70 Evaluation of human periosteum derived cells for bone regeneration Agata, H.
 2006
 38 3S1 p. 5-6
2 p.
 artikel
71 71 Expansion of bovine chondrocytes in hypoxic conditions promotes the formation of cartilage-like matrix in high density micromass cultures Egli, R.J.
 2006
 38 3S1 p. 34-35
2 p.
 artikel
72 Experience with loading-dose ibandronate von Moos, R.
 2006
 38 3S1 p. 86-
1 p.
 artikel
73 Experimental study of biological mechanism in treating of fracture by chinese herbal medicine Luo, Z.G.
 2006
 38 3S1 p. 14-15
2 p.
 artikel
74 Expression of collagen VI in bone and osteosarcoma cell lines reveals its role in the development of bone matrix Wilson, P.J.M.
 2006
 38 3S1 p. 21-
1 p.
 artikel
75 69 Expression of Runx2 transcription factor in sperm Jeong, J.H.
 2006
 38 3S1 p. 34-
1 p.
 artikel
76 For how long can a single infusion of zoledronic acid suppress bone resorption in patients with cancer treatment induced bone loss (CTIBL)? Brown, J.E.
 2006
 38 3S1 p. 70-
1 p.
 artikel
77 FRA-2 is a novel regulator of bone development affecting osteoclasts, osteoblasts and chondrocytes Bozec, Aline
 2006
 38 3S1 p. 9-
1 p.
 artikel
78 Frontiers of Skeletal Biology 2006
 38 3S1 p. 1-4
4 p.
 artikel
79 Functional analysis of HB-EGF during osteoclastogenesis Nakamura, T.
 2006
 38 3S1 p. 29-
1 p.
 artikel
80 68 Glucosamine sulfate inhibits IL-1-stimulated chondrocyte aggrecanase expression, and is effective in a rat model of osteoarthritis Chiusaroli, R.
 2006
 38 3S1 p. 33-
1 p.
 artikel
81 Higher bone mineral density and bone mineral content in endemic fluorosis: Human study Khandare, Arjun L.
 2006
 38 3S1 p. 13-
1 p.
 artikel
82 70 Human embryonic stem cell-derived connective tissue progenitors for tissue engineering Cohen, S.
 2006
 38 3S1 p. 34-
1 p.
 artikel
83 Human farnesyl diphosphate synthase crystal structures with active and inactive bisphosphonates Evdokimov, A.
 2006
 38 3S1 p. 49-
1 p.
 artikel
84 Hyperhomocysteinemia increases bone fragility and reduces osteoblast activity in adult wistar rats Herrmann, M.
 2006
 38 3S1 p. 11-12
2 p.
 artikel
85 Ibandronate and Clodronate cause-dose and time- dependent apoptosis of human sarcoma cells in vitro Kurth, A.A.
 2006
 38 3S1 p. 54-
1 p.
 artikel
86 Ibandronate improves osseointegration of cementless metal implants to a similar extent either given continuously or as a single equivalent dose Eberhardt, C.
 2006
 38 3S1 p. 48-
1 p.
 artikel
87 Ibandronate improves osseointegration of implants in experimental osteoporosis Kurth, A.A.
 2006
 38 3S1 p. 54-55
2 p.
 artikel
88 Ibandronate in fracture healing – an overview Habermann, B.
 2006
 38 3S1 p. 74-
1 p.
 artikel
89 Ibandronate® in the adjuvant treatment of locally advanced prostate carcinoma (PCa) Lindenmeir, T.
 2006
 38 3S1 p. 80-
1 p.
 artikel
90 Ibandronate relieves pain and improves quality of life in breast cancer patients with metastatic bone disease: Phase III data Body, J.J.
 2006
 38 3S1 p. 69-70
2 p.
 artikel
91 74 Identification of a CTCF-binding site between the Rxrb and the Col11a2 genes, and its functions Murai, J.
 2006
 38 3S1 p. 36-
1 p.
 artikel
92 Immunogenic properties of renal cell carcinoma favour osteoclast recruitment in bone metastases Perut, F.
 2006
 38 3S1 p. 29-30
2 p.
 artikel
93 Impact of bisphosphonate therapy on the nature of spine metastases from breast cancer: An observational study Skrinskas, T.
 2006
 38 3S1 p. 84-
1 p.
 artikel
94 Improvement of Osseointegration of Cementless Metal Implant under Ibandronate is dose-dependent Eberhardt, C.
 2006
 38 3S1 p. 48-
1 p.
 artikel
95 Increased cortical bone in betacellulin transgenic mice Schneider, M.R.
 2006
 38 3S1 p. 18-
1 p.
 artikel
96 Influence of electro-acupuncture on bone mineral density, bone strength and ultrastructure in ovariectomized rats Luo, Z.G.
 2006
 38 3S1 p. 27-28
2 p.
 artikel
97 Inhibition of FIAT (factor inhibiting ATF4-mediated transcription) by rna knockdown upregulates osteocalcin transcription in osteoblastic cells Yu, V.W.C.
 2006
 38 3S1 p. 19-
1 p.
 artikel
98 Inhibition of FPP-synthase in osteoblasts may explain the blunting of the bone anabolic response to PTH observed after chronic exposure of rats to bisphosphonates Gasser, J.A.
 2006
 38 3S1 p. 50-51
2 p.
 artikel
99 Inhibition of post-translational prenylation causes sustained activation of RAC, Cdc42 and Rho GTPases Coxon, Fraser P.
 2006
 38 3S1 p. 45-
1 p.
 artikel
100 Intravenous and oral ibandronate have better safety and tolerability profiles than zoledronic acid: Evidence from comparative phase III trials Bergström, B.
 2006
 38 3S1 p. 68-69
2 p.
 artikel
101 Intravenous (IV) bisphosphonates for osteopenic cancer survivor women: An alternative treatment Rodríguez, E.
 2006
 38 3S1 p. 72-73
2 p.
 artikel
102 Intravenous zoledronic acid effectively decreases serum calcium in primary hyperparathyroidism Misiorowski, W.
 2006
 38 3S1 p. 80-81
2 p.
 artikel
103 Investigations into the kinetic mechanism of inhibition of farnesyl diphosphate synthase by nitrogen containing bisphosphonates Dunford, J.E.
 2006
 38 3S1 p. 47-48
2 p.
 artikel
104 73 Ionotropic glutamate receptors are functional in human fibroblast-like synoviocytes and modulate IL-6 and MMP-2 expression Flood, S.J.
 2006
 38 3S1 p. 36-
1 p.
 artikel
105 IPP/ApppI production and cellular drug uptake in synergistic action of doxorubicin and zoledronic acid Kuokkanen, J.
 2006
 38 3S1 p. 54-
1 p.
 artikel
106 Jones fractures in patients with metastatic breast cancer (MBC) Poznak, C. Van
 2006
 38 3S1 p. 85-
1 p.
 artikel
107 Klotho is an essential molecule responsible for tissue specific FGF23 signaling Urakawa, I.
 2006
 38 3S1 p. 20-
1 p.
 artikel
108 Loading-dose ibandronate with maintenance dosing for the palliation of metastatic bone pain: The Bon-I-Pain and Bon-O-Pain trials Body, J.J.
 2006
 38 3S1 p. 69-
1 p.
 artikel
109 Local treatment of giant cell tumors by a bone substitute material and a bisphosphonate Kurth, A.A.
 2006
 38 3S1 p. 77-
1 p.
 artikel
110 Low dose PTH, insufficient to induce cyclic AMP or C-fos, stimulates an anabolic gene response in human osteoblasts in vitro Buckley, K.A.
 2006
 38 3S1 p. 10-11
2 p.
 artikel
111 Mechanisms of bone cancer pain relief with bisphosphonates Mantyh, P.
 2006
 38 3S1 p. 56-
1 p.
 artikel
112 Microcrack initiation occurs more easily in vertebrae from beagles treated with alendronate than with risedronate Iwata, K.
 2006
 38 3S1 p. 42-
1 p.
 artikel
113 Molecular modeling comparison of nitrogen-containing bisphosphonates of varying potency co-crystalized in farnesyl diphosphate synthase Ebetino, F.H.
 2006
 38 3S1 p. 49-50
2 p.
 artikel
114 New strategies based on zoledronic acid/tipifarnib combination in the therapy of prostate cancer Caraglia ⁎ , M.
 2006
 38 3S1 p. 44-
1 p.
 artikel
115 Nitrogen-containing bisphosphonates and alkylamines activate Vγ9Vδ2 T cells through a common mechanism involving inhibition of the mevalonate pathway Thompson, Keith
 2006
 38 3S1 p. 63-
1 p.
 artikel
116 Nitrogen-containing bisphosphonates may exert potent estrogenic effects on MCF-7 breast cancer cells growth Journé, F.
 2006
 38 3S1 p. 52-
1 p.
 artikel
117 Non-viral osteoprotegerin gene transfer inhibits the tumor progression and prolongs survival in a mouse experimental model of osteosarcoma Lamoureux, F.
 2006
 38 3S1 p. 26-
1 p.
 artikel
118 Novel vitamin B6 derivative of alendronate rapidly absorbed following oral administration Zinnen, S.
 2006
 38 3S1 p. 64-
1 p.
 artikel
119 Optimal timing of bolus intravenous zoledronic acid in a rat fracture model Amanat, N.
 2006
 38 3S1 p. 43-
1 p.
 artikel
120 Oral ibandronate and intravenous zoledronic acid in metastatic breast cancer patients: Comparative bone turnover marker and safety data Body, J.J.
 2006
 38 3S1 p. 69-
1 p.
 artikel
121 Oral ibandronate versus intravenous zoledronic acid for breast cancer patients with skeletal complications: The swog trial Rivkin, S.
 2006
 38 3S1 p. 82-
1 p.
 artikel
122 Osteoclasts but not osteoblasts are affected by bisphosphonate bound to a calcified substrate Schindeler, A.
 2006
 38 3S1 p. 62-63
2 p.
 artikel
123 Osteoprotegerin (OPG) expression in breast tumours and bone metastases Van Poznak, C.
 2006
 38 3S1 p. 31-32
2 p.
 artikel
124 Oxytocin: An estrogen-controlled autocrine-paracrine modulator of osteoclastogenesis and bone resorption Colaianni, G.
 2006
 38 3S1 p. 24-25
2 p.
 artikel
125 Pain reduction with oral and intravenous ibandronate treatment for metastatic bone disease of breast cancer Kurth, A.A.
 2006
 38 3S1 p. 77-78
2 p.
 artikel
126 Pharmacokinetics of ibandronate in myeloma patients with renal insufficiancy Bergner, R.
 2006
 38 3S1 p. 68-
1 p.
 artikel
127 Phase III trial of oral ibandronate versus intravenous zoledronic acid in multiple myeloma: Study design Jackson, G.
 2006
 38 3S1 p. 75-76
2 p.
 artikel
128 Postnatal growth and formation of the mandible in intact rat Luzin, V.
 2006
 38 3S1 p. 15-
1 p.
 artikel
129 Prevention of breast cancer cell adhesion to bone in vitro by bisphosphonates is mediated by their inhibitory effect on protein prenylation Garrioch, Sweyn
 2006
 38 3S1 p. 59-60
2 p.
 artikel
130 Prevention of post-bone marrow transplantation bone loss with zoledronate Arabi, A.
 2006
 38 3S1 p. 66-
1 p.
 artikel
131 Program: What is New in Bisphosphonates? 2006
 38 3S1 p. 38-41
4 p.
 artikel
132 Prostaglandin E2 EP4 agonist (ONO-4819) accelerates BMP-induced osteoblastic differentiation Nakagawa, K.
 2006
 38 3S1 p. 16-17
2 p.
 artikel
133 Protective effect of vitamin D3 on methylprednisolone acetate (MPA) induced loss of bone metabolism markers and bone mineral density in the lumbar spine of rat Sobhani, A.
 2006
 38 3S1 p. 19-
1 p.
 artikel
134 RANKL negatively regulates the binding of a 125 KDa transcriptional repressor within the mouse Tcirg1 gene promoter during osteoclastogenesis Beranger, G.E.
 2006
 38 3S1 p. 23-24
2 p.
 artikel
135 Rapid increase in levels of circulating osteoprotegerin (OPG) in patients with tumour-induced bone disease following zoledronic acid administration Holen, I.
 2006
 38 3S1 p. 75-
1 p.
 artikel
136 75 Recombinant human cartilage-derived retinoic acid sensitive protein (CD-RAP)—a novel treatment option for osteochondral defects Pippig, S.D.
 2006
 38 3S1 p. 36-37
2 p.
 artikel
137 Reduced bone pain by intensive bisphosphonate-therapy of new diagnosed bone metastases Kurth, A.A.
 2006
 38 3S1 p. 77-
1 p.
 artikel
138 Refining the use of hydroxyapatite column chromatography to reveal differences in relative binding affinities of bisphosphonates Lawson, M.A.
 2006
 38 3S1 p. 55-
1 p.
 artikel
139 Release of ATP from human osteoblastic cell lines and primary osteoblasts occurs via exocytosis Mwaura, B.K.
 2006
 38 3S1 p. 11-
1 p.
 artikel
140 Renal insufficiency in cancer patients: Prevalence and implications on anticancer drugs management. Final results of the “IRMA” study Launay-Vacher, V.
 2006
 38 3S1 p. 78-79
2 p.
 artikel
141 Renal safety of ibandronate in patients with relapsed and refractory multiple myeloma Glasmacher, A.
 2006
 38 3S1 p. 73-
1 p.
 artikel
142 Resistin, an adipocytokine, stimulates osteoblast and osteoclast proliferation Cornish, J.
 2006
 38 3S1 p. 9-
1 p.
 artikel
143 Resorbing osteoclasts increase the availability of mineral-bound bisphosphonates to non-resorbing cells Coxon, Fraser P.
 2006
 38 3S1 p. 45-46
2 p.
 artikel
144 Risedronate demonstrates fracture efficacy in postmenopausal women whether there is a BMD gain or loss during treatment Watts, N.
 2006
 38 3S1 p. 86-
1 p.
 artikel
145 Role of CCN1 protein in osteoclast-mediated bone resorption after low-level cadmium Bhattacharyya, M.H.
 2006
 38 3S1 p. 24-
1 p.
 artikel
146 S0307: A phase III trial of bisphosphonates as adjuvant therapy for primary breast cancer Gralow, J.
 2006
 38 3S1 p. 74-
1 p.
 artikel
147 Selective targeting of DR5 circumvents resistance of MG-63 osteosarcoma to trail-induced apoptosis Locklin, R.M.
 2006
 38 3S1 p. 13-14
2 p.
 artikel
148 Sequence-dependent synergistic effects of ibandronate in combination with antiestrogens on growth inhibition of estrogen receptor-positive breast cancer cells Journé, F.
 2006
 38 3S1 p. 52-53
2 p.
 artikel
149 Short-term efficacy of alendronate in wheel-chair bound patients Pluskiewicz, W.
 2006
 38 3S1 p. 81-82
2 p.
 artikel
150 Single dose zoledronic acid treatment is superior to continuous treatment in enhancing hard callus formation and strength without delayed remodelling McDonald, M.M.
 2006
 38 3S1 p. 57-
1 p.
 artikel
151 sRANKL, OPG and rank are modulated by pressure and age of donor in macrophages and osteoblasts Evans, C.E.
 2006
 38 3S1 p. 25-
1 p.
 artikel
152 67 Storage conditions are crucial to maintain phenotypes in osteochondral grafts Bastian, J.D.
 2006
 38 3S1 p. 33-
1 p.
 artikel
153 Structure-activity relationships of bisphosphonate analogues Coxon, F.P.
 2006
 38 3S1 p. 46-
1 p.
 artikel
154 Substitution of the R1 hydroxyl and C1 phosphate of risedronate produces differences in elution profiles on hydroxyapatite ceramic chromatographic columns Xia, Z.
 2006
 38 3S1 p. 63-64
2 p.
 artikel
155 Surgical induction of temporomandibular ankylosis: An animal model Shi, X.J.
 2006
 38 3S1 p. 18-19
2 p.
 artikel
156 Systemic and local zoledronate treatment of bilateral necrosis of caput femoris caused by SLE-a case report Åstrand, J.
 2006
 38 3S1 p. 66-67
2 p.
 artikel
157 Target enzyme specificity, potency and potential lack of side-effects of novel phosphonocarboxylate analogues of bisphosphonates Coxon, F.P.
 2006
 38 3S1 p. 46-47
2 p.
 artikel
158 Teriparatide and HRT against osteoporosis of woman Bazarra-Fernández, A.
 2006
 38 3S1 p. 7-
1 p.
 artikel
159 The AZURE trial – does adjuvant zoledronic acid reduce recurrence in patients with high-risk localised breast cancer? Burkinshaw, R.
 2006
 38 3S1 p. 70-71
2 p.
 artikel
160 The bisphosphonate–ester apomine does not act by inhibiting protein prenylation, but enhances the effects of lovastatin on myeloma cells Roelofs, Anke J.
 2006
 38 3S1 p. 60-
1 p.
 artikel
161 The crosstalk between bone and cancer cells: Alterations of osteoblasts in gene expression and behavior are metastasis-type specific Ackermann, K.
 2006
 38 3S1 p. 5-
1 p.
 artikel
162 The direct antitumor activity of bisphosphonates in vivo depends on their bone mineral affinity Fournier, P.
 2006
 38 3S1 p. 45-
1 p.
 artikel
163 The effects of tumor necrosis factor-α on osteoclast formation depend on the haematopoietic precursors Portenier, Jeannette
 2006
 38 3S1 p. 26-27
2 p.
 artikel
164 The high prevalence of vitamin D insufficiency in postmenopausal women (PMW) with osteoporosis (OP) has not been significantly reduced after 12 months of treatment with Ca and vitamin D Georgiadis, A.E.
 2006
 38 3S1 p. 73-
1 p.
 artikel
165 the influence of vitamin D supplementation on OPG/RANKL/RANK system in postmenopausal women: the six month clinical study Krivošíková, Z.
 2006
 38 3S1 p. 27-
1 p.
 artikel
166 The small molecule nmp is an enhancer of bone regeneration Weber, F.E.
 2006
 38 3S1 p. 20-21
2 p.
 artikel
167 72 The synergistic effect of extracellular nucleotides and EGF on C-Fos expression in two breast cancer cell lines Gartland, A.
 2006
 38 3S1 p. 35-
1 p.
 artikel
168 Three-dimensional osteoblast cultures on synthetic hydroxy-apatite support: Molecular characterization and vascularization study after implant on chick allantochorial membrane Mancini, L.
 2006
 38 3S1 p. 19-20
2 p.
 artikel
169 Three dimensional reconstruction of haversian canals using X-ray micro-computed tomography Mohsin, S.
 2006
 38 3S1 p. 16-
1 p.
 artikel
170 Three structural snapshots of the FPPS catalytic cycle revealed by X-ray analyses of the human enzyme Rondeau, J.-M.
 2006
 38 3S1 p. 61-
1 p.
 artikel
171 thyroid ultrastructure in the mature rat’s organism under influence of zometa Koveshnikov, V.
 2006
 38 3S1 p. 53-54
2 p.
 artikel
172 Tolerability of oral and intravenous ibandronate (BONDRONAT®) treatment of metastatic bone disease in breast cancer Schäfer, I.
 2006
 38 3S1 p. 83-
1 p.
 artikel
173 Trabecular bone turnover is reestablished sooner in ovariectomized rats after withdrawal of treatment with risedronate vs alendronate Fuchs, R.K.
 2006
 38 3S1 p. 50-
1 p.
 artikel
174 Treating bone metastases from solid tumors with a combination of ibandronate and radiotherapy: Clinical evaluation and radiological assessment Vassiliou, V.
 2006
 38 3S1 p. 85-86
2 p.
 artikel
175 Understanding the binding mechanism of substrates and bisphosphonates with farnesyl pyrophosphate synthase—A microcalorimetry study Bitsch, F.
 2006
 38 3S1 p. 44-
1 p.
 artikel
176 Uptake of bone-related matrix proteins into implanted deproteinized bovine bone mineral Bosshardt, D.D.
 2006
 38 3S1 p. 8-9
2 p.
 artikel
177 Use of cDNA microarrays to estimate gene modulation profiles induced by zoledronic acid treatment in androgen resistant prostate cancer cell line (PC3) Santini, D.
 2006
 38 3S1 p. 61-62
2 p.
 artikel
178 Use of combined calcitonin and etidronate in bone mass loss with HIV-infection Bazarra-Fernández, A.
 2006
 38 3S1 p. 67-
1 p.
 artikel
179 Why do patients with metastatic breast cancer (MBC) continue to have bone destruction despite bisphosphonate (BP) use? A pathologic review Ooi, W.S.
 2006
 38 3S1 p. 81-
1 p.
 artikel
180 Wnt signaling in osteoblast differentiation and bone formation Bodine, P.V.N.
 2006
 38 3S1 p. 8-
1 p.
 artikel
181 X-ray and 2D NMR analyses of the binding of nitrogen-containing bisphosphonate drugs to human FPPS Rondeau, J.-M.
 2006
 38 3S1 p. 61-
1 p.
 artikel
182 Zoledronate prevents bone loss after stroke Poole, K.E.S.
 2006
 38 3S1 p. 82-
1 p.
 artikel
183 Zoledronic acid and PTH increase bone mass and mechanical strength following radiation therapy for osteolytic bone metastases Arrington, S.A.
 2006
 38 3S1 p. 43-
1 p.
 artikel
184 Zoledronic acid in adjuvant treatment of early breast cancer Alonso, B.
 2006
 38 3S1 p. 65-
1 p.
 artikel
185 Zoledronic acid in adjuvant treatment of early breast cancer after twelve months of the first cycle Alemán, R.
 2006
 38 3S1 p. 66-
1 p.
 artikel
186 Zoledronic acid induced IPP/ApppI accumulation in different cancer cell lines Mönkkönen, H.
 2006
 38 3S1 p. 58-
1 p.
 artikel
187 Zoledronic acid induces osteosarcoma cell death by aif translocation and cell cycle arrest in S and G2/M phases Ory, B.
 2006
 38 3S1 p. 59-
1 p.
 artikel
188 Zoledronic acid reduces bone loss in men with prostate cancer receiving goserelin Casey, R.
 2006
 38 3S1 p. 71-
1 p.
 artikel
189 Zoledronic acid slows down rat primary chondrosarcoma development, recurrente tumor progression after intralesional curretage and increases overall survival Gouin, F.
 2006
 38 3S1 p. 51-
1 p.
 artikel
190 Zoledronic acid versus ibandronate comparative evaluation in breast cancer patients with bone metastases: The NCRI zice trial Barrett-Lee, P.J.
 2006
 38 3S1 p. 67-
1 p.
 artikel
191 Zoledronic acid (ZOL) and letrozole (LET) induce synergistic levels of apoptosis in breast cancer cells Neville-Webbe, H.L.
 2006
 38 3S1 p. 58-59
2 p.
 artikel
                             191 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland